Responses
Other responses
Jump to comment:
- Published on: 28 April 2022
- Published on: 28 April 2022Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer?
Dear editor,
I read with great appreciation the study “Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial” [1]. The authors aimed to evaluate the clinical impact of a structured exercise intervention in patients with operable oesophageal cancer during Neoadjuvant chemotherapy compared with those on a standard treatment pathway (p. 1); and for that, they carried out a prospective non-randomised trial. The paper has an elegant rationale and I am sure that will generate new research, however, exist some methodological fragile that may compromise the results.1st, as this study specifically assessed the impact of exercise on measures of chemotherapy response (p. 1), the exercise program should be clearly described (e.g., exercise volume, time under tension, duration, cadence and range of motion, heart and respiratory rate). 2nd, the authors established moderate intensity for exercise, based on WHO recommendations for physical activity level (p. 2), however, physical activity is different of physical exercise; besides, they did not use the repetition-maximum [2] test to assess the strength of the patients and plan the intensity individually.
3rd, the authors added aerobic exercise (p. 2) to the structured program, but it was unclear how patients were assessed for this intervention (what velocity? Incline? Heart rate? Vo2?). 4th, the strategy for sample...
Show MoreConflict of Interest:
None declared.